Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
labmedica.com
Microbiology
Features Subscription Partner Sites Journal Info
RANDOX LABORATORIESAB SCIEXVeolia WATER

MRSA Identified Using Nasal Swabs

By Labmedica International staff writers
Posted on 13 Sep 2012


Methicillin-resistant Staphylococcus aureus (MRSA) infections have been detected by nasal swabbing using agar culture methods.

The proportion of patients with MRSA that were correctly identified by nasal swabs has been compared with multiple body site testing using agar and nutrient broth culture.

A cross-sectional study has been carried out by the Health Protection Scotland (Glasgow, UK) on adult patients admitted to 36 general specialty wards of two large hospitals in Scotland (UK). Patients were screened for MRSA via multiple body site swabs such as nasal, throat, axillary, perineal, wound, and invasive device sites. These were cultured individually on Brilliance MRSA chromogenic agar (Oxoid; Basingstoke, UK) and pooled in nutrient broth. Suspect colonies were confirmed by a coagulase test using the Prolex Staph Xtra Latex kit (Pro-Lab Diagnostics; Bromborough, UK). Combined results from all sites and cultures provided a gold-standard estimate of true MRSA prevalence.

The scientist found that nasal screening performed better than throat, axillary, or perineal screening, but only identified 66% of true MRSA carriers against the gold standard at an overall prevalence of 2.9%. Axillary screening performed least well. Combining nasal and perineal swabs gave the best two-site combination with 82%. When combined with realistic screening compliance rates of 80%-90%, nasal swabbing alone probably detects just over half of true colonization in practice. Swabbing of clinically relevant sites such as wounds and indwelling devices, is important for a small but high-prevalence group.

The investigators concluded that nasal swabbing is the standard method in many locations for MRSA screening. Its diagnostic efficiency in practice appears to be limited, however, and the resource implications of multiple body site screening have to be balanced against a potential clinical benefit whose magnitude and nature remains unclear. The study was published in the August 2012 issue of the journal Infection Control and Hospital Epidemiology.

Related Links:

Health Protection Scotland
Oxoid
Pro-Lab Diagnostics





ELISA Kit
ELISA Kit
HbA1c Analyzer
HbA1c Analyzer
CHEMILUMINESCENCE IMMUNOASSAY SYSTEM
CHEMILUMINESCENCE IMMUNOASSAY SYSTEM

More Products

Latest Microbiology News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
SIEMENS DIAGNOSTICS :
Siemens Healthcare Diagnostics Anti-CCP: A Clinical Evaluation Whitepaper

Download Whitepaper
Events
ELA – European Lab Automation congress
06 Jun 2013 - 07 Jun 2013


European Human Genetics Conference 2013
08 Jun 2013 - 11 Jun 2013


8th Forum on Oxidative Stress and Aging
12 Jun 2013 - 14 Jun 2013


More events
GLOBETECH PUBLISHING
Latest Issue

View Digital Edition
Subscribe / Renew
AACC
GREINER-BIO-ONE
ALTO MARKETING LIMITED
KARL HECHT GMBH & CO KG
77 ELEKTRONIKA
BioPorto Diagnostics
DIASOURCE
  labmedica.com Copyright © 2000-2013 Globetech Media. All rights reserved.
Privacy Policy